Skip to content
BHP

Tirzepatide licensed dose regimens

Licensed dose regimens

Reviewed by the BestHealingPeptides Editorial Team ·

Tirzepatide is a licensed prescription only medicine in the UK (Mounjaro), not a research peptide, and this page does not provide a dosing recommendation. The table below summarises the licensed regimen set out in section 4.2 of the UK Summary of Product Characteristics on the emc for Mounjaro KwikPen, which applies to both type 2 diabetes and weight management; the dose and titration for any individual are set by their prescriber, and the current product information should always be checked.

For full mechanistic context, study summaries, and safety information, see the main Tirzepatide research profile.

Reported routes of administration

  • Subcutaneous injection (once weekly; licensed route)

Reported half-life

Elimination half-life of approximately 5 days (UK SmPC section 5.2). Tirzepatide is highly bound to plasma albumin (99%) through its C20 fatty diacid moiety, which prolongs the half-life and supports once-weekly subcutaneous dosing. Steady-state exposure is achieved after 4 weeks of once-weekly dosing (SmPC section 5.2).

See the dedicated half-life reference page for fuller pharmacokinetic context.

Licensed dose regimens

Licensed Tirzepatide dose regimens
IndicationRouteRegimenNote
Type 2 diabetes (Mounjaro, MHRA-licensed)Subcutaneous, once weeklyStart 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; if needed, increase in 2.5 mg steps after a minimum of 4 weeks on the current dose. Adults: maintenance doses 5, 10 and 15 mg, maximum 15 mg once weekly. Children and adolescents aged 10 to under 18 years: maintenance doses 5 mg and 10 mg, maximum 10 mg once weeklyMounjaro SmPC section 4.2. No data in paediatric patients under 50 kg with a BMI below the 85th percentile; caution is advised when escalating to 10 mg in paediatric patients under 60 kg. When added to a sulphonylurea or insulin, a reduction in the dose of the sulphonylurea or insulin may be considered; metformin and SGLT2 inhibitors can be continued. NICE TA924 sets the criteria for NHS use in type 2 diabetes.
Weight management in adults (Mounjaro, MHRA-licensed)Subcutaneous, once weeklySame schedule as above: start 2.5 mg once weekly for 4 weeks, then 5 mg; increases in 2.5 mg steps after a minimum of 4 weeks on the current dose. Maintenance doses 5, 10 and 15 mg; maximum 15 mg once weeklyMounjaro SmPC section 4.2. Stopping rule: if patients have been unable to lose at least 5% of their initial body weight 6 months after titrating to the highest tolerated dose, a decision is required on whether to continue treatment. The SmPC does not license weight management under 18 years. In SURMOUNT-1 the 5, 10 and 15 mg arms had mean weight changes of -15.0%, -19.5% and -20.9% at 72 weeks. NICE TA1026 sets the criteria for NHS use in obesity.
Administration and missed doses (both indications)Subcutaneous injection into the abdomen or thigh, or into the back of the upper arm if another person gives the injectionOnce weekly, at any time of day, with or without meals. A missed dose can be given within 4 days; if more than 4 days late, skip it. The day of weekly dosing can be changed if the interval between doses is at least 3 daysMounjaro SmPC section 4.2. No dose adjustment is required for renal or hepatic impairment, but experience in severe disease and in end-stage renal disease is limited, so caution is advised.
Licensed regimens summarised from the UK Summaries of Product Characteristics. Not a dosing recommendation; follow your prescriber.